Efficacy and safety of bortezomib in patients with refractory and relapsed multiple myeloma (MM) outside clinical trials: Results from the catalan myeloma/amyloid study group (Gemmac)

被引：0
|
作者：
Cibeira, M. T.
Garcia, A.
Rosinol, L.
Petit, J.
Oriol, A.
Abella, E.
Soler, J. A.
Plensa, E.
Callis, M.
Gonzalez, Y.
Macia, J.
Orriols, J.
Escoda, L.
Tutusaus, M.
Heras, G.
Monzo, S.
Herranz, M. J.
Garcia, M.
Sureda, A.
Blade, J.
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] H Germans Trias Pujol, Badalona, Spain
[3] H Mar Barcelona, Barcelona, Spain
[4] H Vall Hebron Barcelona, Barcelona, Spain
[5] H Josep Trueta Girona, Girona, Spain
[6] H Joan XXIII Tarragona, Althaia Xarxa Assistencial Manresa, Tarragona, Spain
[7] H Joan XXIII, Tarragona, Spain
[8] H Sagrat Cor Barcelona, Barcelona, Spain
[9] H Santa Tecla, Tarragona, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [41] DARATUMUMAB COMBINED WITH DEXAMETHASONE AND LENALIDOMIDE OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS: REPORT FROM THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP
    Fazio, F.
    Franceschini, L.
    Tomarchio, V.
    Rago, A.
    Garzia, M. G.
    Cupelli, L.
    Bongarzoni, V.
    Rosati, S.
    Gumenyku, S.
    Antolino, G.
    Siniscalchi, A.
    Proietti, G.
    Piciocchi, A.
    De Fabritiis, P.
    De Rosa, L.
    Caravita, T.
    Annibali, O.
    Cantonetti, M.
    Petrucci, M. T.
    HAEMATOLOGICA, 2021, 106 (10) : 92 - 92
  • [42] Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma
    White, Darrell
    Kassim, Adetola
    Bhaskar, Birbal
    Yi, Jing
    Wamstad, Karen
    Paton, Virginia E.
    CANCER, 2013, 119 (02) : 339 - 347
  • [43] Brazilian Relapsed Refractory Multiple Myeloma Patients Treated with Teclistamab Outside of Clinical Trials as an Expanded Access Program
    Pericole, Fernando
    Lima, Juliana Souza
    Ottoni, Erica
    Ribeiro, Glaciano
    Crusoe, Edvan de Queiroz
    Cunha, Rafael
    Costa, Abel
    Cury, Priscilla
    Maciel, James
    Hungria, Vania T. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S196 - S197
  • [44] The Efficacy and Safety of Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Real Clinical Practice : A Study of the Korean Multiple Myeloma Working Party (KMMWP)
    Lee, Ho Sup
    Min, Chang Ki
    Kim, Kihyun
    Lee, Je-Jung
    Bang, Soo-Mee
    Kim, Jin Seok
    Eom, Hyeon Seok
    Lee, Jae Hoon
    Yoon, Do Hyun
    Kim, Inho
    Shin, Ho-Jin
    Park, Yong
    Jo, Jae-Cheol
    Lee, Won Sik
    Mun, Yeung-Chul
    Kim, Hyo Jung
    Park, Seong Kyu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E74 - E75
  • [45] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma
    Berenson, James R.
    Martinez, Daisy
    Safaie, Tahmineh
    Silagan, Noemi
    To, Jennifer
    Spektor, Tanya M.
    Forouzan, Eli
    Swift, Regina
    Eades, Benjamin
    Eshaghian, Shahrooz
    Schwartz, Gary
    Boccia, Ralph V.
    Yang, Honghao H.
    Moezi, Mehdi M.
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2021, 138
  • [46] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
    Suvannasankha, Attaya
    Bahlis, Nizar
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Oriol, Albert
    Voorhees, Peter M.
    Alonso, Aranzazu A.
    Callander, Natalie S.
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Lamacchia, John
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne. C.
    Zhou, Xiangdong
    Gupta, Ira
    Opalinska, Joanna
    Nooka, Ajay K.
    CANCER, 2024, 130 (15) : 2629 - 2641
  • [47] Preliminary safety and efficacy results from an international phase 3b study for expanded access to bortezomib in 624 patients with relapsed and/or refractory multiple myeloma.
    Mikhael, Joseph R.
    Belch, Andrew
    Prince, Miles
    Lucio, Maria Nambo
    Maiolino, Angelo
    Corso, Alessandro
    Petrucci, Maria Teresa
    Mieczyslaw, Komarnicki
    Stewart, A. Keith
    BLOOD, 2006, 108 (11) : 1007A - 1007A
  • [48] Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study
    van de Donk, Niels W. C. J.
    Popat, Rakesh
    Larsen, Jeremy
    Minnema, Monique C.
    Jagannath, Sundar
    Oriol, Albert
    Zonder, Jeffrey A.
    Richardson, Paul G.
    Rodriguez Otero, Paula
    Badros, Ashraf Z.
    Stadtmauer, Edward
    Bringhen, Sara
    Campagnaro, Erica
    Siegel, David S.
    Gamberi, Barbara
    Gironella Mesa, Mercedes
    Sonneveld, Pieter
    Tuong Vi Nguyen
    Di Micco, Antonia
    Sorrell, April
    Chen, Min
    Amatangelo, Michael
    Kueenburg, Elisabeth
    Lonial, Sagar
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 17 - 18
  • [49] Efficacy and safety of a modified daratumumab/bortezomib/dexamethasone regimen using once weekly bortezomib in relapsed refractory multiple myeloma
    Abousaud, Marin
    Dressler, Emily
    Duda, Jessica
    Johnson, Emily
    Kennedy, LeAnne
    Rodriguez, Cesar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E150 - E151
  • [50] Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment
    Blade, Joan
    Sonneveld, Pieter
    Miguel, Jesus E. San
    Sutherland, Heather J.
    Hajek, Roman
    Nagler, Arnon
    Spencer, Andrew
    Robak, Tadeusz
    Cibeira, M. Teresa
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Orlowski, Robert Z.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (06): : 352 - 355
12345